MET Stock Analysis — MetLife
Sector: Financials
AI Verdict
MetLife trades at 8.4x next year's earnings with nearly 94% EPS growth expected, making it cheap for the growth you're getting if its scale-driven moat keeps delivering.
Competitive Moat
MetLife is a global insurance provider with a scale advantage in underwriting, distribution, and regulatory compliance that smaller competitors struggle to match. Its entrenched relationships with large employers and institutional clients create sticky, recurring revenue streams that are difficult to disrupt.
Summary
MetLife's forward P/E of 8.4x and expected 93.9% EPS growth make it a standout among insurers for value-focused investors.
Where It Stands
The stock is up 4.34% over the past year, trades at just 8.4x next year's earnings versus a sector median of 14x, and its RSI of 46.8 suggests neutral momentum with no overbought risk.
Key Metrics
- RSI: 46.8 — Neutral
- Trailing P/E: 16.4x
- Forward P/E: 8.4x
- PEG Ratio: 0.17
- Earnings Growth: +0.9%
- Revenue Growth: +0.1%
- Market Cap: $54.4B
- Dividend Yield: 0.03%
- 1-Year Return: 4.34%
- 52-Week High: $89.62
- 52-Week Low: $67.33
Analyst Consensus
16 Buy · 7 Hold · 0 Sell (23 analysts)
Bull Case
With analysts projecting 93.9% EPS growth and a forward P/E of 8.4x, you're paying a bargain price for a near-doubling of earnings.
Bear Case
If the forward P/E reverts to the sector median of 14x after earnings normalize, short-term valuation upside could disappear, and the current RSI of 46.8 leaves little technical support if sentiment sours.
Catalyst to Watch
Watch for quarterly earnings to confirm that the forecasted 93.9% EPS growth is materializing — any miss could quickly erase the valuation gap.